Anygen 과거 수익 실적
과거 기준 확인 0/6
Anygen's earnings have been declining at an average annual rate of -6.8%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 0.05% per year.
주요 정보
-6.8%
수익 성장률
-1.9%
EPS 성장률
Biotechs 산업 성장 | 11.7% |
매출 성장률 | -0.05% |
자기자본 수익률 | -92.7% |
순이익 | -136.9% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
수익 및 비용 분석
Anygen 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 6,004 | -8,221 | 1,962 | 1,178 |
31 Mar 24 | 6,423 | -9,209 | 2,170 | 1,402 |
31 Dec 23 | 5,611 | -9,079 | 2,059 | 1,494 |
30 Sep 23 | 6,217 | -7,889 | 1,969 | 1,514 |
30 Jun 23 | 6,292 | -8,530 | 2,149 | 1,614 |
31 Mar 23 | 6,700 | -6,138 | 2,014 | 1,709 |
31 Dec 22 | 8,662 | -6,205 | 2,047 | 2,099 |
30 Sep 22 | 11,137 | -1,240 | 1,945 | 2,050 |
30 Jun 22 | 11,367 | -414 | 2,045 | 1,995 |
31 Mar 22 | 11,902 | -2,038 | 2,029 | 1,759 |
31 Dec 21 | 10,267 | -1,690 | 1,933 | 1,240 |
30 Sep 21 | 7,488 | -3,394 | 1,962 | 1,213 |
30 Jun 21 | 8,228 | -3,338 | 1,981 | 1,105 |
31 Mar 21 | 8,475 | -2,163 | 2,263 | 1,133 |
31 Dec 20 | 8,516 | -2,462 | 2,773 | 1,150 |
30 Sep 20 | 8,614 | -4,610 | 3,205 | 1,172 |
30 Jun 20 | 8,210 | -5,129 | 3,581 | 1,268 |
31 Mar 20 | 6,831 | -6,188 | 3,819 | 1,289 |
31 Dec 19 | 6,277 | -6,645 | 3,980 | 1,367 |
30 Sep 19 | 5,987 | -8,420 | 3,805 | 1,289 |
30 Jun 19 | 5,328 | -8,468 | 3,501 | 1,267 |
31 Mar 19 | 4,622 | -8,434 | 3,099 | 1,341 |
31 Dec 18 | 4,114 | -7,164 | 2,417 | 1,072 |
30 Sep 18 | 3,533 | -3,277 | 2,114 | 967 |
30 Jun 18 | 3,854 | -1,898 | 1,738 | 665 |
31 Mar 18 | 4,463 | 99 | 1,524 | 171 |
31 Dec 17 | 4,552 | 448 | 1,464 | 189 |
30 Sep 17 | 4,736 | -15 | 2,276 | 161 |
30 Jun 17 | 4,502 | -630 | 2,244 | 221 |
31 Mar 17 | 4,362 | -1,304 | 2,024 | 411 |
31 Dec 16 | 4,177 | -1,647 | 1,834 | 361 |
30 Jun 16 | 3,994 | -2,794 | 719 | 542 |
31 Dec 15 | 3,722 | -2,574 | 601 | 768 |
31 Dec 14 | 3,677 | -362 | 689 | 68 |
31 Dec 13 | 4,007 | 153 | 655 | 94 |
양질의 수익: A196300 is currently unprofitable.
이익 마진 증가: A196300 is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: A196300 is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.
성장 가속화: Unable to compare A196300's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: A196300 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
자기자본 수익률
높은 ROE: A196300 has a negative Return on Equity (-92.7%), as it is currently unprofitable.